Subscribe To

Price Alert Latest News Economic Calendar News

ANPCY / ANGLE hails study where Parsortix showed ability to help select patients for immunotherapy treatments

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) said pilot data from a study in ovarian cancer patients showed how its Parsortix system could be used to select patients for clinical trials who are likely to respond better to immunotherapy treatments. Andrew Newland, chief executive of ANGLE, said the data showcased the utility of the Parsortix system for the unbiased isolation of multiple subsets of circulating tumour cells (CTCs) in ovarian cancer patients. Read More

Demo Live Account See Partner Details

Content Topics

Teamviewer

Ag

Tmv

De

Parsortix

Showed

Ability

Select

Patients

Immunotherapy

Treatments

Stock

ANPCY

Posted: Jan 21 2022, 02:59

Author Name: Proactive Investors

ANPCY News

By Proactive Investors
October 25, 2023

ANGLE technolgy could help provide a more targeted approach to head and neck cancer

ANGLE plc, a leading company in liquid biopsy technology, has unveiled promising research findings that could help transform the treatment of head and

By Proactive Investors
October 3, 2023

ANGLE hails the latest breast cancer study

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy and cancer diagnostics specialist, has hailed a study that could change the way doctors monitor a

By Proactive Investors
September 29, 2023

ANGLE technology showcased in six poster presentations at cancer event

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a specialist in liquid biopsy and circulating tumour cell (CTC) diagnostics, said that nine posters featuring its gr

By Proactive Investors
September 7, 2023

ANGLE PLC: Making solid commercial progress

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a specialist in liquid biopsies for cancer detection, is showing early signs of progress despite industry headwinds.

By Proactive Investors
September 7, 2023

ANGLE makes encouraging start to year; momentum set to continue in H2

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy company specialising in circulating tumour cell (CTC) diagnostic solutions, anticipates continue

By Proactive Investors
September 4, 2023

ANGLE unveils groundbreaking cancer diagnostic tool

ANGLE plc, a frontrunner in liquid biopsy technology, has unveiled its latest innovation, the Portrait Flex CTC assay - a cutting-edge diagnostic tool

By Proactive Investors
June 5, 2023

ANGLE makes two key appointments to help deliver "strategic and commercial objectives"

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of the Parsortix liquid biopsy, has enhanced its executive roster with two key appointments: Brett Swa

By Proactive Investors
May 25, 2023

ANGLE technology to be used in cancer clinical trial

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a pioneer of liquid biopsy technology, announced a significant contract win with Artios Pharma. Under the deal ANG

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.